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The conversion of proteins from their native state to misfolded oligomers is associated with, and thought to
be the cause of, a number of human diseases, including Alzheimer’s disease, Parkinson’s disease, and
systemic amyloidoses. The study of the structure, mechanism of formation, and biological activity of protein
misfolded oligomers has been challenged by the metastability, transient formation, and structural heteroge-
neity of such species. In spite of these difficulties, in the past few years, many experimental approaches have
emerged that enable the detection and the detailedmolecular study ofmisfolded oligomers. In this review,we
describe the basic and generic knowledge achieved on protein oligomers, describing the mechanisms of
oligomer formation, the methodologies used thus far for their structural determination, and the structural
elements responsible for their toxicity.Introduction
Polypeptide chains have a high intrinsic propensity to self-
assemble into a variety of misfolded aggregates, ranging from
dimers to highly organized fibrils consisting of thousands of
protein molecules (Chiti and Dobson, 2006; Dobson, 2003;
Eichner and Radford, 2011; Jahn and Radford, 2008). Protein
aggregation can occur starting from any of the conformational
states adopted by the initially monomeric protein, including the
fully unfolded state, the folded state, and any partially folded
states, although the latter have the highest propensity to self-
assemble (Bemporad et al., 2006; Chiti and Dobson, 2006).
Protein aggregation is deleterious for any living organism as it
prevents a protein fromadopting its functional state and because
the resulting protein oligomers are inherently toxic (Chiti and
Dobson, 2006; Walsh and Selkoe, 2007). In fact, the failure of
proteins to remain soluble—occurring as a consequence of
mutation, aging, local increases of protein concentration,
medical treatment, or other circumstances—results in patholog-
ical states that are very diverse and depend on the protein under-
going aggregation and on the tissues involved (Chiti andDobson,
2006).
The end product of protein aggregation processes occurring
in pathology is generally represented by extracellular amyloid
fibrils or structurally equivalent intracellular inclusions, often
associating further to form larger assemblies that are visible
with optical microscopy. However, protein oligomers forming
early during the process of amyloid fibril formation or, alterna-
tively, released by mature fibrils, have acquired increasing
importance over the past 10–15 years. This is first due to the
fact that formation of protein oligomers is a key event of the over-
all process of amyloid fibril formation and has been long re-
garded as the rate-limiting step, responsible for the lag phase
in aggregation kinetics (Morris et al., 2009; Orte et al., 2008).
Second, oligomers are thought to be the pathogenic species
associated with the formation of amyloid in diseases (BillingsChemistry & Bioet al., 2005; Bucciantini et al., 2002; Cleary et al., 2005; Koffie
et al., 2009; Lesne´ et al., 2006; Winner et al., 2011). As the impor-
tance of protein oligomers was increasingly realized, many
reports have appeared with information on their mechanism of
formation and structure, with the ultimate goal of identifying
the structural determinants of their pathogenicity, the molecular
events of disease onset, and the molecular targets for thera-
peutic intervention. In this review, we describe how oligomers
form, the structure of such species, including the technological
progress recently achieved to gain insight into their molecular
structure and the structural elements responsible for their
toxicity.
Mechanism of Formation of Amyloid Oligomers
One of the most widely accepted mechanisms proposed for
the assembly of monomers into oligomers is the so-called
‘‘nucleation growth’’ mechanism (Jarrett and Lansbury, 1993;
Lomakin et al., 1996). According to this mechanism, monomers
convert into a nucleus through a thermodynamically unfavorable
process taking place in the lag phase of amyloid aggregation
kinetics (pathway A/ C/D/ H/ G; red arrows in Figure 1).
The nucleus can be defined as the least thermodynamically
stable species in solution (i.e., the multimer of minimal size
able to initiate assembly; Morris et al., 2009). Alternatively, the
nucleus can also be defined as the aggregate size after which
the association rate exceeds the dissociation rate for the first
time (Ferrone, 1999). The nucleus could even be a monomer
that acts as a template for the rapid growth of the amyloid aggre-
gate through the association of further monomers (H/ G/ I
in Figure 1) (Lomakin et al., 1996).
After the nucleation growth model was proposed, the concept
of nucleus was investigated in further detail and other more
accurate models were proposed. In the nucleated conforma-
tional conversion, native monomers initially convert into mis-
folded conformations, which initiate self-assembly through alogy 19, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 315
Figure 1. Mechanisms Leading to the Formation of Protein Oligomers
Proteins initially populate a native conformation (A) in which amyloid-prone segments (in green) are structured/buried and unable to initiate polymerization.
However, native states can convert, under certain conditions, into aggregation-prone states, a native-like (B), a partially folded (C), and an unfolded (D) monomer.
In these conformational ensembles, aggregation-prone segments become exposed to the solvent and can establish intermolecular interactions, with the resulting
formation of early aggregates, which can be native-like aggregates (E) or molten aggregates of misfolded monomers (F). The early aggregates convert later into
amyloid oligomers competent for fibril nucleation (G). The pathway that transits through the native-like state (A/ B/ E/ G, indicated by green arrows) is
referred to as native-like aggregation. The pathway that transits through fully or partially unfoldedmonomers (A/C/D/ F/G, indicated by light blue arrows) is
the nucleated conformational conversion. There is finally another possible pathway, in which a misfolded monomer converts into an amyloid-competent
monomer (A/ C/D/ H, indicated by red arrows). This acts as a template for formation of the oligomer (G). This pathway is usually referred to as the nucleation
growth mechanism. The red asterisks denote two steps (E/ G and F/ G) whose removal makes oligomer formation an off-pathway process that leads to
species unable to further convert into amyloid fibrils.
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oligomer lacking persistent structure (A/ C/D/ F; light blue
arrows in Figure 1) (Serio et al., 2000). This aggregated species
then undergoes a structural reorganization into an amyloid-like
oligomer, which acts as a nucleus (F/ G). The nucleus rapidly
triggers aggregation as other molten oligomers acquire the
amyloid conformation through a templating or induced-fit mech-
anism at the aggregate ends (Serio et al., 2000). This leads to the
formation of higher order oligomers and eventually fibrils (G/ I).
These two models differ for a number of aspects. While in the
nucleation growth mechanism, the monomer directly interacts
with the nucleus and the nucleus could be as small as a
monomer, in the nucleated conformational conversion both the
building block and the nucleus are described as oligomeric
species. Moreover, in the first model the rate-limiting step is
represented by the formation of the nucleus (C/D / H in
Figure 1), whereas in the second model oligomers form rapidly,
with the rate-limiting step being the conversion of the misfolded
oligomer into the amyloid oligomer (F/ G in Figure 1). Different
reports support either model. In many cases, the nucleation
growth mechanism seems to account for the observed aggrega-
tion kinetics (Bhattacharyya et al., 2005; Morris et al., 2008).
Furthermore, proteins populating amyloid conformations directly316 Chemistry & Biology 19, March 23, 2012 ª2012 Elsevier Ltd All rat the monomer level have been described (Sandal et al., 2008),
while some authors have reported (e.g., in the case of insulin)
template-dependent conversion of monomers at the growing
fibril end (Pease et al., 2010). However, it was recently shown
that the monomers can rapidly form small globular oligomers
that are kinetically competent to slowly convert to amyloid
oligomers and later to amyloid fibrils following the nucleated
conformational conversion. This was observed for example in
ADA2h (Cerda`-Costa et al., 2007), Ab (Lee et al., 2011; Petty
and Decatur, 2005), huntingtin (Thakur et al., 2009), and IAPP
(Wei et al., 2011).
In fact, it has been observed that formation of oligomers by
a protein can occur through different pathways. In some cases,
a certain pathway can be enhanced by changes in solution
parameters such as pH and protein concentration (Bader et al.,
2006; Gosal et al., 2005) or by introducing mutations (Bitan
et al., 2003; Kumar and Udgaonkar, 2009). In other cases, aggre-
gation can proceed via competing pathways occurring concom-
itantly in the same sample (Jain and Udgaonkar, 2011; Kayed
et al., 2007; Kaylor et al., 2005). Differences in pathways imply
differences in morphology (Bader et al., 2006; Gosal et al.,
2005), dimensions (Bitan et al., 2003), and compactness (Kaylor
et al., 2005) of the resulting oligomers. It is important to note thatights reserved
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conversion from a nonamyloid to an amyloid conformation
occurs (Kumar and Udgaonkar, 2009). Thus, the two models
described earlier could be the limit cases of a more complicated
scenario where multiple pathways are accessible and selected
depending on the conditions.
A possible unifying view able to combine the two apparently
competing models described earlier is that the pathway preva-
lently followed depends on the structural nature of both the
amyloid-competent monomer and the oligomer (Figure 1). If
the amyloid-competent conformational ensemble hasa sufficient
degree of dynamical fluctuations and hydrophobic clusters
exposed to the solvent, then formation of molten oligomers lack-
ing persistent structure is fast, while conversion of the molten
oligomer into an amyloid oligomer takes place only later and is
accelerated by the template effect (nucleated conformational
conversion; light blue arrows in Figure 1). If the misfolded confor-
mational ensemble has not sufficient hydrophobic clusters
exposed to the solvent and/or is prone to hydrogen bonding,
then the other mechanism is likely to take place (nucleation
growth; red arrows in Figure 1). Consistently, it was recently
shown that short hydrophobic peptides give rise prevalently to
misfolded oligomers, while peptides prone to establish intermo-
lecular hydrogen bonds with their side chains rapidly form b-rich
nuclei (Bleiholder et al., 2011).
So far, we have considered that a folded protein needs to
unfold to generate a partially or fully unfolded state to become
competent for aggregation. However, it was recently shown
that normally folded proteins retain a small but significant
tendency to form amyloid without the need of reactions that
cross the major energy barrier for unfolding. In these cases,
the amyloid-competent state is best described as a monomeric
conformation that possesses an extent of secondary and tertiary
structure still comparable with that of the fully folded state yet
being endowed with aberrant features that enable self-assembly
(A/ B in Figure 1, indicated by green arrows). Formation of this
conformational ensemble, usually referred to as a native-like
state, can be induced either as a consequence of a local unfold-
ing event, as in the case of Cu,Zn-uperoxide dismutase (Banci
et al., 2005), b2-microglobulin (Eakin et al., 2006), and transthyr-
etin (Olofsson et al., 2004; Quintas et al., 2001) or due to cooper-
ative increase in thermal fluctuations, as it was shown in the case
of lysozyme (Canet et al., 2002) and Sso AcP (Pagano et al.,
2010). In either case, aggregation-prone segments that are nor-
mally buried or structured in the fully folded state become
exposed to the solvent or gain flexibility, triggering the formation
of native-like aggregates (B/E); these then convert directly into
amyloid-like oligomers and fibrils (E/ G/ I).
Are Oligomers On- or Off-Pathway Species?
One long debated issue is whether protein oligomers represent
on-pathway structures that must be necessarily populated along
the pathway leading to fibril formation or rather off-pathway
particles that are placed at a dead end of the reaction scheme
and act only as a reservoir of monomers, while fibril formation
proceeds directly through association of monomers to the
amyloid nucleus. In the case of the immunoglobulin light chain
LEN, it was shown that oligomers represent off-pathway
species: Fibril formation occurs only after the amyloid-Chemistry & Bioincompetent oligomer dissociates and monomers convert into
a more amyloidogenic conformation (Souillac et al., 2003; Souil-
lac et al., 2002). Other off-pathway oligomers have been reported
forb2-microglobulin (Gosal et al., 2005) andalbebetin (Gosal et al.,
2005;Morozova-Rocheet al., 2004; Souillac et al., 2002). A recent
computational study has shown that the amyloid-b peptide (Ab)
can form off-pathway oligomers; these assemblies are too curvy,
are too compact, and display an amount of b-structure not
enough for the conversion into larger amyloid oligomers (Yu and
Zheng, 2011). Despite these reports, many proteins, such as the
PI3-SH3 domain, barstar, sup35p, IAPP, and Ab itself have
been shown to form on-pathway oligomers that represent either
the building block or the nucleus for fibril formation (Bader et al.,
2006; Ehrnhoefer et al., 2008;Harper et al., 1997;Kumar andUdg-
aonkar, 2009; Serio et al., 2000; Wei et al., 2011).
Of note, by varying the solution conditions, one can modulate
the nature of the oligomers, switching from b-rich toxic on-path-
way oligomers to unstructured nontoxic off-pathway assemblies
(Ehrnhoefer et al., 2008; Ladiwala et al., 2010). Changes from off-
to on-pathway oligomers can be also obtained by mutating the
peptide sequence (Jain and Udgaonkar, 2011). Furthermore, it
was shown, using short polyglutamine-containing huntingtin
fragments, that the same sample can contain contemporane-
ously on-pathway and off-pathway oligomers, with the latter
acting as a reservoir of monomers that support fibril elongation
(Jayaraman et al., 2011). Thus, these observations may suggest
a scenario where structural features of the oligomers determine
their off-pathway or on-pathway nature. For example, highly
stable oligomers may populate a deep minimum in the energy
landscape; consequently, their conversion into an amyloid-like
conformationmay be slower than their dissociation. Consistently
with this idea, the structural rearrangement from off-pathway to
on-pathway oligomers was shown to consist in a significant
increase of disordered secondary structure, an increase in
solvent accessibility, and a decrease in intrinsic stability of the
soluble oligomeric species (Souillac et al., 2003).
Protein misfolded oligomers do not form only as on- or off-
pathway species. They can also form as species released
directly bymature fibrils. In particular, it has been recently shown
that mature fibrils are not necessarily highly stable end products
populating the deepest minima in the energy landscape (Eichner
and Radford, 2011) and that amyloid fibrils can directly release
monomers and oligomers (I/ G in Figure 1). It was shown, for
example, that fibrils of the Ab peptide are destabilized by the
presence of lipid vesicles and brain lipid extracts, releasing toxic
oligomers (Martins et al., 2008). It is interesting that these ‘‘back-
ward’’ oligomers are biophysically and biochemically similar to
the ‘‘forward’’ oligomers (i.e., to the oligomers formed along
the pathway going from monomers to fibrils) (Martins et al.,
2008). Leakage of Ab oligomers from fibrils has also been
observed in vivo (Koffie et al., 2009; Lesne´ et al., 2006). The toxic
effect observed in a mouse model expressing the Ab peptide
was shown to be proportional to the amount of oligomers
released from amyloid plaques surrounding cells (Lesne´ et al.,
2006). Solubilization of transthyretin, b2-microglobulin, and
insulin fibrils by doxycycline, tetracyclins, and weakly basic
pH, respectively, also led to toxic oligomers (Cardoso and
Saraiva, 2006; Giorgetti et al., 2011; Heldt et al., 2011b). Hence,
these observations show that amyloid fibrils can be secondarilylogy 19, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 317
Table 1. Techniques Used to Study Protein Oligomers at the Molecular Level
Technique Obtained information Advantages References
H/D exchange coupled to
fragmentation methods
and MS
Involvement of different protein
segments in secondary structure
formation
Noninvasive detection of
multiple oligomers, good
resolution (if fragmentation is
obtained with top-down
techniques)
(Kheterpal et al., 2006; Kheterpal
and Wetzel, 2006; Pan et al.,
2011)
H/D exchange coupled to both
MS and NMR
Involvement of individual
residues in secondary structure
formation
Detection of multiple oligomers,
information at the residue level,
high resolution
(Carulla et al., 2009)
Solution NMR Secondary and tertiary
structures in low-molecular-
weight oligomers
High resolution, information on
both secondary and tertiary
structures at the residue level
(Pagano et al., 2010; Yu et al.,
2009)
Solid-state NMR Secondary and tertiary structure
in high-molecular-weight
oligomers
Information at the residue level (Chimon et al., 2007)
DEST solution NMR Secondary and tertiary
structures in oligomers
Information at the residue level,
applicable to low- and high-
molecular-weight oligomers
(Fawzi et al., 2011)
Labeling with fluorescent
probes
Intermolecular interactions
between labeled residues, burial
of labeled residues
Information at the residue level,
standard lab instrumentation
required
(Campioni et al., 2010; Krishnan
and Lindquist, 2005)
Scanning proline mutagenesis Regions of the sequence
involved in oligomer formation
Standard lab instrumentation
required, good resolution
(Williams et al., 2005)
Small angle X-ray scattering Simultaneous detection of size
and shape
Detection of multiple oligomers (Langkilde and Vestergaard,
2009)
Single-molecule fluorescence
(TCCD or FRET)
Compactness, stability and size
of oligomers
Direct monitoring of single
oligomer particles, detection
of multiple oligomers
(Orte et al., 2008, 2011)
Ion mobility MS Mass and shape of oligomers Direct monitoring of single
oligomer particles, detection
of multiple oligomers
(Bernstein et al., 2009; Bleiholder
et al., 2011; Pease et al., 2010)
FRET sensor Direct observation of oligomer
formation in vivo
Noninvasive, applicable in vivo (Kaminski Schierle et al., 2011)
Chemistry & Biology
Reviewtoxic via the release of cytotoxic oligomers and that fibrils could
speed up oligomer formation directly acting as a reservoir of
amyloid nuclei.
Experimental Approaches to Study the Oligomer
Structure
A number of biophysical and biochemical methods have been
used to obtain structural information on protein oligomers. These
include far-UV circular dichroism (CD), Fourier transform infrared
(FTIR), and hydrogen/deuterium (H/D) exchange coupled to
mass spectrometry (MS) to determine the content of b sheet
and a-helical structure; ultracentrifugation, size exclusion chro-
matography, photo-induced crosslinking of unmodified proteins
(PICUP), and dynamic light scattering to determine the oligo-
meric state (i.e., the amount of protein molecule in the oligo-
mers); ANS and acrylodan binding to determine the solvent
exposure of hydrophobic clusters; Thioflavine T (ThT) and Congo
Red (CR) binding to determine the level of structural order;
imaging techniques such as transmission electron microscopy
(TEM) and atomic force microscopy (AFM) to determine the
morphology and size; and so forth. Although such techniques
provide valuable information on the average structure and oligo-
meric state of the aggregates, they do not reveal their molecular318 Chemistry & Biology 19, March 23, 2012 ª2012 Elsevier Ltd All rdetails at the residue level. This is a challenging problem as
protein misfolded oligomers, similarly to amyloid fibrils, cannot
be crystallized and generally have a size prohibitive for solution
nuclear magnetic resonance (NMR), thus preventing the use of
techniques commonly used in structural biology. In addition to
the complexities encountered for fibrils, oligomers are structur-
ally more heterogeneous andmetastable than fibrils, thus raising
further problems.
In the past 5 years, however, a number of approaches have
been introduced for a deep molecular characterization of the
oligomers (Table 1). H/D exchange followed by peptide fragmen-
tation and MS has proven a valuable technique, exploiting the
principle that backbone amide hydrogen atoms are protected
to H/D exchange if they are engaged in stable b sheet or a-helical
contacts. Oligomers are subjected to H/D exchange upon incu-
bation in deuterated water (D2O), fragmented with limited pro-
teolysis or top-down techniques (e.g., electron capture dis-
sociation) and then analyzed with MS (Kheterpal et al., 2006;
Kheterpal and Wetzel, 2006; Pan et al., 2011). The determination
of the extent of protection to deuterium incorporation in the frag-
ments detected in the mass spectra has revealed the extent to
which the fragments are engaged in secondary structure forma-
tion in the intact oligomers, often with a resolution down toights reserved
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methods coupled to top-down techniques have the advantage
of being noninvasive and photographing the solution of interest
(no purification, chemical modification, or treatment of the oligo-
mers is required), of detecting and structurally determining
a multiplicity of coexisting species rather than their average
structural properties, and of obtaining a spatial resolution
down to individual residues (Pan et al., 2011).
In another study, H/D exchange and MS methods were
coupled to NMR (Carulla et al., 2009). The PI3-SH3 protein
domain was incubated at low pH in the presence of D2O, under
conditions favoring its rapid unfolding and subsequent aggrega-
tion. After a variable time interval (Dtagg), the sample was trans-
ferred into H2O for a fixed time and the H/D exchange was
then quenched by freeze drying and dissolution in DMSO, which
is a denaturing and disaggregating solvent preventing H/D
exchange. Samples left to aggregate for variable Dtagg time
values were then analyzed with both electrospray ionization-
MS (ESI-MS) and NMR. This approach allowed the concomitant
detection of various oligomeric species during aggregation to
follow their kinetics of appearance and disappearance and to
determine their structure in terms of amide protection to H/D
exchange at the residue level.
Other H/D independent studies aimed at determining the
degree of structural flexibility and solvent exposure of side chains
in the aggregates. Twenty mutants of the HypF-N protein con-
taining a single cysteine residue at various positionswere labeled
with pyrene and allowed to aggregate under two dif-
ferent conditions; the fluorescence spectra of the resulting
samples were acquired, revealing in each case whether the
pyrene moiety was buried inside the oligomers and in contact
with another pyrenemoiety or rather flexible and solvent exposed
(Campioni et al., 2010). This study allowed the identification of the
regions of the sequence that were most structured and buried in
the interior of the protein oligomers, revealing significant differ-
ences between the two oligomer populations that could explain
differences in their cytotoxicity (discussed later).
Low-molecular-weight oligomers have also been studied with
conventional solution NMR (Pagano et al., 2010; Yu et al., 2009),
whereas large aggregates have been successfully studied with
solid state NMR using approaches normally applied to amyloid
fibrils (Chimon et al., 2007). A novel, very interesting solution
NMR technique, named dark-state exchange saturation transfer
(DEST), has been very recently presented to probe the structure
of Ab40 and Ab42 protofibrils and circumvent the problems of
limiting solution NMR to small oligomers (Fawzi et al., 2011). In
all such cases, secondary and/or tertiary information of themole-
cules forming the oligomers have been obtained for individual
residues.
Detailed molecular structure of protein oligomers was also ob-
tained for Ab40 protofibrils using scanning proline mutagenesis
(Williams et al., 2005). This approach consisted in the systematic
substitution of all peptide residues with proline and in the subse-
quent evaluation of the equilibrium between soluble and aggre-
gated peptide for all mutants having a single substitution.
Mutants that produced the largest changes in such equilibrium
relative to the wild-type peptide were meant to indicate the
involvement of the mutated residues in the protofibrillar struc-
ture. Another interesting method is small angle X-ray scattering.Chemistry & BioThis technique gives information about shape and dimensions of
oligomers ranging from 1 to about 100 nm (Langkilde and Vester-
gaard, 2009) and has been used in different systems such as
insulin (Vestergaard et al., 2007), a-synuclein (Giehm et al.,
2011), and the immunoglobulin light chain LEN (Souillac et al.,
2002).
Many of the approaches described here to study protein olig-
omers were inspired by previous studies successfully applied to
stable amyloid-like fibrils. The complexities arising from the
structural heterogeneity and metastability of the oligomers has
been circumvented with various strategies; for example, by
using compounds stabilizing the oligomers (Williams et al.,
2005), protocols based on the disaggregation of fibrils at high
pH (Heldt et al., 2011a), proteins forming stable oligomers (Cam-
pioni et al., 2010) or by using MS methods that allow the
concomitant detection of various species in a sample (Carulla
et al., 2009; Pan et al., 2011). The study performed on the PI3-
SH3 domain provides a nice example of an approach to effec-
tively circumvent such problems, as the oligomeric species
could be studied in spite of their transient appearance and coex-
istence with other species (Carulla et al., 2009).
The problem of structural heterogeneity is also being over-
come by a number of emerging cutting-edge methodologies
that allow the oligomers to be studied at the single molecule
level. In two-color coincident detection (TCCD), two subpopula-
tions of a protein sample are labeled with two different probes.
By inducing the coaggregation of the resulting subpopulations,
it is possible to observe the formation of individual oligomers
through the coincident detection of the two fluorescent probes
(Orte et al., 2008). Intensity of the observed two fluorescence
signals provided information about oligomer size distribution.
The same approach was extended to perform single-molecule
fluorescence resonance energy transfer (FRET) studies (i.e.,
monitoring the energy transferred from a donor probe to an
acceptor probe through measurements of the fluorescence
emitted by the latter); the observed fluorescence arises from
FRET events within individual oligomers and provided informa-
tion about the distance between the two labeled positions
(Orte et al., 2011). Finally, in ion mobility MS, the oligomers
were separated in two steps: (1) according to their mobility in
a chamber containing a carrier buffer gas that opposes their
ion motion and (2) according to their mass-to-charge ratio. This
technique gave direct information about mass, size, and shape
for individual oligomer species, detecting concomitantly the
presence of different oligomer subpopulations, and was applied
to Ab (Bernstein et al., 2009; K1oniecki et al., 2011), b2-microglo-
bulin (Smith et al., 2010), and insulin (Pease et al., 2010), as well
as to a set of synthetic peptides (Bleiholder et al., 2011).
It is interesting that a noninvasive FRET sensor has been
recently set up to monitor in vivo the formation of oligomers
and their interconversion (Kaminski Schierle et al., 2011). In
this approach, changes in fluorescence lifetime reflect changes
in the oligomer status and can be related to differences in
toxicity, providing a new tool to study noninvasively oligomer-
related toxicity in vivo.
Structure of the Oligomers
The existence of parallel pathways in protein aggregation,
and the metastability of the various species accumulating duringlogy 19, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 319
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diverse characteristics. This complexity has led to the utilization
of different criteria for their classification; for example, on the
grounds of their size, b sheet content (or other purely structural
characteristics), stability to SDS solubilization or other treat-
ments, productive role in amyloid fibril formation, reactivity to
conformation-specific antibodies, and so forth. Even by focusing
on a single system such as Ab, a full description of the various
oligomers described in the literature would require a review or
book chapter per se. Therefore, in this section, we try to describe
the key structural features shared by protein oligomers from
different peptides/proteins and how such structures change as
aggregation proceeds.
When aggregation is initiated by fully or largely unfolded
monomers in the nucleated conformational conversion, the initial
oligomers exhibit a large variety of conformations, with mono-
mers still adopting a disordered structure. For example, using
PICUP and CD spectroscopy, it was found that the early aggre-
gates formed by Ab40 and Ab42 are dimers-tetramers and pen-
tamers-hexamers, respectively, with a poor level of structure;
these acquire b sheet structure later on in the process at the
level of protofibrils (Bitan et al., 2003). The appearance of early
unstructured aggregates of Ab40 with unstable b sheet structure
was also detected in other two more recent studies, performed
independently with H/D exchange (coupled to MS) and FIAsH
labeling, respectively, with larger oligomers containing stable
b sheet structure forming later (Lee et al., 2011; Qi et al., 2008).
Furthermore, with tryptophan fluorescence, it was shown that
the initial aggregates formed by a-synuclein display unfolded
monomers that expose hydrophobic residues to the solvent
(Dusa et al., 2006). Characterization of the aggregation pathway
of the pH-unfolded PI3-SH3 domain by pulse-labeling H/D
exchange coupled to MS and NMR showed that species
detected early in the aggregation process are disordered on
the basis of the low degree of amide hydrogen exchange protec-
tion (Carulla et al., 2009). Very recently, it has been shown, by
means of ion mobility MS, that a set of peptides form initially
unfolded assemblies (Bleiholder et al., 2011). Molten globule-
like self-associating oligomers have been found to be populated
prior to fibril formation also for IAPP (Wei et al., 2011).
If aggregation starts from native-like states, the early aggre-
gates formed at the beginning of the process display monomers
populating native-like states (Banci et al., 2005; Olofsson et al.,
2004; Pagano et al., 2010). In the case of the model protein
Sso AcP, aggregation is not just initiated by a native-like state;
the native-like structure persists when the protein forms the
initial aggregates (Pagano et al., 2010). In a mutant form of
superoxide dismutase type-1, native dimers interact to form
larger oligomers stabilized by transient interactions between
electrostatic loops from different dimers; these oligomers retain
monomers in a native-like conformation (Banci et al., 2005).
Transthyretin assembles into aggregates in which monomers
exhibit six b strands in a native-like conformation while two
edge strands are misfolded (Olofsson et al., 2004). Early oligo-
mers from insulin have been shown to be rich in a-helical struc-
ture (Bouchard et al., 2000; Vestergaard et al., 2007).
It therefore emerges that initial aggregates are far from the
amyloid structure. In fact, regardless of the aggregation pathway
followed by a protein, the initial aggregates display the same320 Chemistry & Biology 19, March 23, 2012 ª2012 Elsevier Ltd All rconformational features observed in the aggregation-competent
monomers. The aggregates do not bind amyloid specific dyes,
nor do they exhibit a significant content of stable b sheet struc-
ture (Lee et al., 2011; Plakoutsi et al., 2005).
As aggregation proceeds, oligomers undergo a structural rear-
rangement into species stabilized by b sheet structure, able to
bind ThT and CR. In addition, oligomers undergo an increase
in dimensions, compactness, stability, and order, still retaining
a nonfibrillar morphology. It was proposed that fibril elongation
of the NM region of the prion Sup35p is initiated following forma-
tion of ordered nuclei by conformational rearrangements of less
structured, molten, oligomeric intermediates (Serio et al., 2000).
During aggregation of human muscle acylphosphatase (mAcP),
oligomers increase their dimensions and disaggregation induced
by dilution into nonamyloidogenic conditions becomes slower as
aggregation proceeds, consistently with an increase in oligomer
stability (Calamai et al., 2005). The study on the pH-unfolded PI3-
SH3 domain mentioned earlier also indicated the late appear-
ance of oligomeric intermediates with highly ordered b sheet
structure (Carulla et al., 2009). Single-molecule studies on the
same protein provided direct evidence that the stable cross-
b structure of the late aggregates emerges via internal reorgani-
zation of disordered oligomers formed during the lag phase of
the self-assembly reaction (Orte et al., 2008). FRET studies
carried out on a-synuclein oligomers showed a decrease in the
distance between Tyr39 and Trp125 from the early oligomers
to the late oligomers, suggesting an increase in compactness
(Kaylor et al., 2005). During aggregation, the NNQQNY peptide
undergoes a transition, beginning near the octamer, from a
natively unstructured assembly to a highly ordered b sheet
assembly (Bleiholder et al., 2011). Finally, as mentioned earlier,
an increase of order and b sheet structure content was also
observed for Ab40 and Ab42 oligomers by different authors and
using different methodologies (Bitan et al., 2003; Lee et al.,
2011; Qi et al., 2008; Sandberg et al., 2010).
Such a structural conversion into b sheet containing amyloid-
like aggregates was also observed for native-like aggregates
containing significant levels of a-helical structure. For example,
the native-like aggregates formed by Sso AcP convert, with
no need of disaggregation, into amyloid-like protofibrils with
a higher level of order, as deduced with ThT fluorescence,
FTIR, and far-UV CD (Plakoutsi et al., 2005). Similarly, a-helical
native-like oligomers of insulin were also shown to convert into
b sheet containing protofibrils, suggesting again a similar
process (Bouchard et al., 2000). The direct conversion from
a-helical to b sheet oligomers without the need of disaggregation
and reassociation was also observed in many molecular
dynamics simulations; for example, for a 17-residue peptide
designed to form a coiled coil trimer (Strodel et al., 2008). In
cases where native-like aggregation involves all-b proteins,
such a structural conversion from early to amyloid-like aggre-
gates has not been yet reported, maybe because of inherent
difficulties for the detection of such a transition where b sheet
structure remains the dominant secondary structure type.
Alternatively, the early oligomers may possess already the struc-
tural characteristics to act as nuclei.
In addition to the observation of a transition from unstructured
(or native-like) oligomers into amyloid oligomers with b sheet
content, the b-structure that forms in early aggregates, whenights reserved
Figure 2. A Schematic Representation of the Structural Rearrangements Occurring during Oligomer Formation
For simplicity, only aggregation starting from fully or largely unfolded monomers is considered (reaction F / G in Figure 1). Amyloidogenic/hydrophobic
segments are in green. The oligomer surface is drawn as a thin black and a thick red dotted line when amyloidogenic/hydrophobic segments are buried and
exposed to the solvent, respectively. While aggregation proceeds (left to right), a set of structural rearrangements takes place: The top and bottom arrows show
the parameters that increase and decrease, respectively. Binding of monomers to early oligomers is isotropic, whereas late oligomers can bind tomonomers only
at the edges. This leads to growth of thin filaments, which eventually originate amyloid fibrils.
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molecules rearrange, for example, through a realignment of
b strands, from a less regular b sheet structure into a b sheet
structure more stable in register (Petty and Decatur, 2005). While
fibrils and large spherical amyloid intermediates (diameter, 15–
35 nm) contain stable parallel b sheets, as determined with
solid-state NMR (Chimon et al., 2007), solution NMR data indi-
cate that small globulomers by Ab (38–48 kDa) have a mixed
parallel and antiparallel b sheet structure (Yu et al., 2009). In
another study, it was found that initial low-molecular-weight olig-
omers of Ab40 have a less extended and more unstable b sheet
structure, judging from H/D exchange data, than larger interme-
diate oligomers forming later (Qi et al., 2008). Consistently with
these data, the oligomeric interfaces of oligomers formed by
a set of model peptides display a variety of sheet-to-sheet pair-
ing angles (Liu et al., 2011). Such internal conversions from vari-
able to regular sheets produce oligomers more productive in
terms of fibril formation, as fibrils have a stable and a regular
b sheet structure (Carulla et al., 2009; Cerda`-Costa et al.,
2007; Orte et al., 2008). This was found directly in a paper where
oligomers exhibiting aligned strands were found to be capable of
forming thermostable, long, rigid, and twisted fibrils, whereas
oligomers without this strand alignment aggregate to form thin,
flexible, and smooth protofibrils (Petty et al., 2005).
Thus, the general picture emerging from all such studies is
that, as aggregation proceeds through a nucleated conforma-
tional conversion process, oligomers undergo a continuous rear-
rangement of structure (Figure 2). This reorganization involves an
increase in size, stability compactness, regularity of the b sheet
structure, and hydrophobic burial. It also implies a decrease in
dynamical fluctuations, exposure of hydrophobic clusters, and
oligomer surface per number of monomers. We show in a
following section that this trend is also related with a decrease
in oligomer toxicity. The conversion may occur through a multi-
plicity of oligomeric states or just as a two-state process, notChemistry & Bionecessarily through four oligomeric states, as depicted in
Figure 2. In addition, each oligomeric state may be considered
as an ensemble of oligomers with distributions of size, structure,
and so forth.
The Oligomers Are Polymorphic in Size and Structure
The aforementioned existence of parallel competing pathways
and the presence ofmultiple species even for the same pathway,
imply that oligomers exist as a number of species with different
morphological and structural properties. This phenomenon is
usually referred to as oligomer polymorphism (Kodali and
Wetzel, 2007; Stefani, 2010). Oligomers exhibit polymorphism
in terms of their size (Mastrangelo et al., 2006), shape (Pountney
et al., 2005), compactness (Kaylor et al., 2005), stability (Calamai
et al., 2005; Souillac et al., 2003), and secondary and tertiary
structure content (Bleiholder et al., 2011; Ehrnhoefer et al.,
2008; Ladiwala et al., 2010; Lee et al., 2011; Serio et al., 2000).
The spectrum of oligomer polymorphism extends even further
if we consider that small oligomers containing both Ab and
a-synuclein molecules form in patients with mixed Alzheimer’s
disease and Parkinson’s disease and in transgenic mice coex-
pressing both proteins (Tsigelny et al., 2008).
Different types of oligomers can coexist in solution at the same
time (Goldsbury et al., 2005; Gosal et al., 2005; Jain and Udg-
aonkar, 2011; Mastrangelo et al., 2006; Relini et al., 2010) and
even in vivo (Winner et al., 2011). The predominance of some
particular species can be determined by a number of factors.
First, mutations can alter the pathway by which oligomers form
and, consequently, the morphology/structure of the oligomers.
For example, in the case of Sso AcP, a set of point mutations
leads to protein variants that aggregate following a pathway
different from that of the wild-type protein, leading to ThT-
binding b-structured oligomers and native-like aggregates,
respectively (Soldi et al., 2008). Addition of two residues at the
C terminus of the Ab peptide is sufficient to change thelogy 19, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 321
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Reviewpopulation of oligomers in equilibrium with the monomer, with
a distribution of monomers to tetramers typical for Ab40 shifting
to a mixture of pentamers and hexamers for Ab42 (Bitan et al.,
2003). In the presence of membrane extracts, different mutants
of Ab40 having single amino acid substitutions also formed
different distributions of polymorphic aggregates (Pifer et al.,
2011). A similar mutation dependence of oligomer formation
was also observed for a-synuclein (Ono et al., 2011).
A second determinant of oligomer polymorphism is the solu-
tion conditions under which aggregation is initiated. In the case
of HypF-N, it was shown that oligomers formed under two
different solution conditions, differing in terms of pH and cosol-
vent composition, exhibit different toxicities (Campioni et al.,
2010), and this can be attributed to differences in compactness
and solvent exposure of hydrophobic clusters (discussed later).
Two different products of lipid peroxidation have recently been
shown to be able to induce a-synuclein oligomers that differ in
terms of morphology, dimensions, compactness, and stability
(Na¨sstro¨m et al., 2011). Finally, the type of seeding can affect
the final fibril morphology/structure, and, consequently, it is
expected to alter the properties of the oligomers that accumulate
prior to fibril formation (Paravastu et al., 2009; Yamaguchi et al.,
2005).
Oligomer polymorphism is not just a relevant phenomenon for
a full description of the structure and mechanism of formation of
oligomers and fibrils but also has many implications in biology. It
was indeed found that expression of different mutants of Ab in
Drosophila qualitatively led to different pathologies (Iijima et al.,
2008) and that different oligomers of a-synuclein and Ab caused
toxicity in cell cultures through different mechanisms (Danzer
et al., 2007; Deshpande et al., 2006). On top of that, it is well
established that polymorphism is a central theme to explain
the propagation of prion strain infectivity (Jones and Surewicz,
2005).
Oligomers In Vitro and In Vivo
An important question is whether the large number of protein
oligomers formed in vitro and described in the literature are
relevant for amyloid fibril formation processes in vivo and their
associated diseases. Using approaches aimed at detecting olig-
omers directly in vivo, a number of studies have revealed the
presence of such species in human patients suffering from
protein deposition diseases or related animal models. This has
been observed, for example, for Ab (Lesne´ et al., 2006; Shankar
et al., 2008), tau (Lasagna-Reeves et al., 2012; Patterson et al.,
2011), huntingtin (Nekooki-Machida et al., 2009), and a-synu-
clein (Tsigelny et al., 2008). Such oligomers, when isolated
from the living specimen and administered to normal rats, have
been shown to cause cognitive impairment in the animals (Lesne´
et al., 2006; Shankar et al., 2008). Models for oligomerization
in vivo are now also being proposed (Larson and Lesne´, 2012).
In addition, conformation-specific antibodies raised against
particular types of exogenous Ab or tau oligomers and showing
no specificity for monomeric or fibrillar protein have been used
to reveal the presence of the same types of oligomers in Alz-
heimer’s disease patients, indicating the existence of such
in vitro-formed oligomers in human patients as well (Hillen
et al., 2010; Kayed et al., 2007, 2003; Lacor et al., 2004;
Lasagna-Reeves et al., 2012, 2011; Noguchi et al., 2009; Patter-322 Chemistry & Biology 19, March 23, 2012 ª2012 Elsevier Ltd All rson et al., 2011). Thus, although our understanding of oligomer
formation mechanisms in vivo remains limited, the existence of
protein oligomers with structural characteristics similar to those
found and characterized in vitro suggests that we can capitalize
on our current knowledge obtained in vitro.
The Structural Determinants of Oligomer-Induced
Cytotoxicity
The progressive elucidation of oligomer structure is starting to
reveal the structural determinants of oligomer toxicity; i.e., the
structural elements that are responsible for the ability of protein
oligomers to interact with the cells and cause their dysfunction.
An important source of information is represented by the large
body of studies on the Ab peptides. Various oligomers have
been described for both the Ab40 and Ab42, which have been
attributed different names, such as Ab-derived diffusible ligands
(ADDLs), protofibrils, prefibrillar oligomers, fibrillar oligomers,
annular protofibrils, amylospheroids, globulomers, spherical
amyloid intermediates, and so forth. The toxicity of many of
such oligomeric species has been measured on cultured cells
using the MTT reduction assay, providing an opportunity to
compare their toxicities.
Figure 3A reports the MTT reduction values measured by
various authors for their studied oligomers versus the size of
the oligomers, expressed as mean molecular weight. The MTT
reduction values reported in the figures were all measured at
a peptide monomer concentration of 2.0–2.7 mM and are thus
comparable between different oligomeric species. The data refer
to both Ab40 and Ab42 as it was shown that the same type of olig-
omers formed by the two species cause similar decreases of
MTT reduction following their addition to the cells (Kayed et al.,
2003; Kayed et al., 2009). A clear trend is present in the plot,
with toxicity decreasing with the size of the oligomers until
a well-defined plateau. It is interesting that the plateau obtained
with the best fitting procedure was not found as 100% but as
83% ± 5%, which is similar to the values reported by different
authors for amyloid fibrils (molecular weight > 2,000 kDa) formed
by both Ab40 and Ab42 (Chafekar et al., 2008; Kayed et al., 2003;
Walsh et al., 1999). The analysis therefore indicates that oligomer
size is an important determinant of oligomer toxicity. In agree-
ment with this analysis, it was found that three classes of small
aromaticmolecules can inhibit Ab42 oligomer toxicity by convert-
ing the small oligomers into large aggregates, fibrils, and mono-
mers, respectively (Ladiwala et al., 2011).
Hydrophobic exposure on the aggregate surface seems to be
another important determinant of oligomer-mediated toxicity. A
pioneristic study that used reconstructed model membranes
rather than cells reported a correlation between hydrophobic
exposure in Ab40 aggregates and membrane fluidity, measured
with bis-ANS fluorescence and membrane fluorescence anisot-
ropy, respectively (Kremer et al., 2000). Later on, a correlation
between hydrophobicity of homopolymeric amino acid stretches
and cytotoxicity of their aggregates has been observed (Oma
et al., 2005). In a more recent study, two types of spherical olig-
omers formed by the HypF-N protein using different protocols
and shown to have indistinguishable size and morphology, as
detected with AFM, were found to have very different toxicities,
with one species found to be nontoxic altogether (Campioni
et al., 2010). With site-directed pyrene labeling, it was foundights reserved
Figure 3. Structural Determinants of Oligomer-Induced Toxicity
(A) Toxicity versus size of Ab40 and Ab42 aggregates. Toxicity is measured by determining MTT reduction by cultured cells following their exposure to oligomers
added to the extracellular medium. Aggregate toxicity was expressed as percentage of MTT reduction relative to untreated cells, where 0% and 100% values are
two extremes of full cell death and full viability, respectively. Values and error bars are from the original papers: prefibrillar oligomers (Kayed et al., 2003), ADDLs
(Lambert et al., 2001), annular protofibrils (Kayed et al., 2009), and amylospheroids (Hoshi et al., 2003). All data were obtained at a peptide concentration in the
range of 2.0-2.7 mM. Aggregate size was expressed as meanmolecular weight of the reported distributions in the original papers, and error bars refer to the width
of the distributions, not SD or SEM: prefibrillar oligomers (Kayed et al., 2007), ADDLs (Gong et al., 2002), annular protofibrils (Kayed et al., 2009), and amylos-
pheroids (Hoshi et al., 2003). Only data for which both molecular weight and MTT reduction values at ca. 2.0–2.7 mM Ab are reported. Data for both Ab40 (filled
circles) and Ab42 (empty circles) are presented, as the same type of oligomers or fibrils formed by the two species cause similar decreases of MTT reduction
(Kayed et al., 2003; Kayed et al., 2009). All data points were fitted to a hyperbolic function of the form y = a * x/(b + x). MTT reduction induced by Ab fibrils (filled and
empty squares for Ab40 and Ab42, respectively) are not taken into account in the fitting procedure and are shown for comparison (Kayed et al., 2003). It is implicit
that their molecular weight is often >2000 kDa.
(B–D) Structural differences between toxic and nontoxic aggregates of HypF-N. (B) Excimer ratio of pyrene (related to the degree of structure formation) versus
number of labeled residue for toxic (red lines) and nontoxic (blue lines) oligomers of HypF-N. (C) II/IIII ratio of pyrene (a correlate of the degree of solvent exposure)
versus number of labeled residue for toxic (red lines) and nontoxic (blue lines) oligomers. (D) Hydropathy profile of HypF-N sequence. The three panels show that
in nontoxic aggregates, unlike the toxic aggregates, the three hydrophobic regions of the sequence are structured and buried inside the oligomers.
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are structured and buried in the nontoxic oligomers, whereas in
the toxic oligomers the same regions are more solvent exposed
and flexible (Figures 3B–3D).
Other studies have appeared very recently on the importance
of hydrophobic exposure for protein aggregate toxicity. Striking
correlations have been found for a number of peptides/proteins
between the toxicity of various forms of aggregates formed
in vitro and added extracellularly to cell cultures, measured
with propidium iodide incorporation, and their solvent exposure
determined with ANS binding (Bolognesi et al., 2010). Another
study has demonstrated that highly amyloidogenic proteins ex-
pressed intracellularly in human embryonic kidney 293T cells
have levels of toxicity, measured with the MTT test, that increase
with the exposure of hydrophobic clusters on the aggregate
surface measured with ANS binding (Olzscha et al., 2011). In
the latter study, the toxicity of the intracellularly expressedChemistry & Bioproteins was attributed to the ability of their aggregates to
interact with a number of multifunctional cellular proteins and
alter their function (Olzscha et al., 2011), whereas in the HypF-N
study, toxicity was attributed to the ability of the extracellularly
added oligomers to interact with the cell membrane and cause
an uptake of calcium (Campioni et al., 2010; Zampagni et al.,
2011). In addition, many other mechanisms of toxicity have
been proposed. Hydrophobic exposure on oligomeric surface
thus seems an important determinant of toxicity, independent
of the mechanism by which oligomers cause cell dysfunction.
Another proposed determinant of oligomer toxicity is the
shape of the aggregates. In particular, it has been proposed
that monomers may associate to form pore-like oligomers that
bind membranes or, alternatively, that monomers directly self-
assemble into pores at the membrane interface (Giehm et al.,
2011; Lashuel et al., 2002a, 2002b; Last et al., 2011). The
proposed consequence of pore formation is that normallylogy 19, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 323
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between the two environments, leading to cellular dysfunction.
Ion-channel oligomers have been observed by TEM for a number
of systems, including Ab, IAPP, a-synuclein, ABri, and ADan (La-
shuel et al., 2002a; Last et al., 2011; Quintas et al., 2001). It
should be emphasized, however, that alternative mechanisms
of oligomer-mediated toxicity have been proposed for all
systems found so far to form annular oligomers. For a-synuclein,
for example, it has recently been proposed that spherical oligo-
mers growing at the membrane edge captures lipids from the
membrane, eventually resulting in membrane disruption (Rey-
nolds et al., 2011). Furthermore, the correlation between size
and toxicity (Figure 3A) includes annular protofibrils (Kayed
et al., 2009), and these oligomers do not significantly deviate
from the observed trend. It is therefore evident that a role for
this specific morphology—and, more generally, for oligomer
shape—in oligomer-mediated toxicity remains elusive.
Although the results reviewed here indicate that protein olig-
omer toxicity is determined by a well-defined set of parameters
such as size and hydrophobic exposure of the oligomers, it is
important to emphasize that toxicity does not reside in one or
limited number of oligomeric forms of a given protein. Different
oligomers from the same protein have been shown to affect
cell viability to some degree. Moreover, the observation that pro-
tein oligomers formed by different proteins share similar levels of
toxicity is itself a strong suggestion that toxicity is a shared prop-
erty of protein misfolded oligomers rather than a characteristic of
a specific structural pattern.
Conclusions
Although the increasing awareness of the existence of a myriad
of different metastable oligomers seemed to make their charac-
terization an impossible task, in the past few years considerable
efforts expended by different researchers has led to the emer-
gence of innovative methodologies that are starting to unveil
the multiple structures of protein misfolded oligomers and the
structural features underlying their toxicity. Oligomer particles
can now be detected at the single molecule level and can be
observed not only in the test tube but even in vivo. The general
emerging picture is that oligomers cannot be described as
a finite number of protein structures, each of them identified
by a defined set of parameters. Oligomers are best described
as a number of conformational ensembles, each containing
an indefinite number of different assemblies that vary, almost
without solution of continuity, in secondary and tertiary struc-
ture, compactness, shape, size, number of monomers, and so
forth. All these parameters contribute to a complex energy
landscape and determine, directly or indirectly, the toxicity
of the oligomers through relationships that are slowly being
revealed.
Of course, much remains to be determined. Key points that
need to be addressed in future research include (1) developing
new and more accurate methodologies for oligomer structure
determination; (2) identifying additional molecular determinants
of oligomer toxicity and themechanisms of action of the resulting
aggregates so that new molecular targets for therapeutic inter-
vention can be identified; (3) understanding the reasons why,
where, and when functional proteins convert into such aggre-
gates, again with the aim of interfering therapeutically with their324 Chemistry & Biology 19, March 23, 2012 ª2012 Elsevier Ltd All rformation; and (4) developing new methodologies to detect
reliably and routinely toxic oligomers in vivo in a noninvasive
way and before disease onset.
It is hoped that such studies will make it possible to fully
describe the ‘‘protein aggregation side’’ of the protein
(mis-)folding landscape, to link our in vitro knowledge with
systems in vivo and to reach a complete understanding of the
relationships between structure and toxicity of protein misfolded
oligomers.
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